venBio Partners LLC
Net buyer this quarter
$519M
7
+$177M
100.0%
Holdings
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026 | |||||
 PHVS | $161M | 30.92% | 7.12% | +0.1% | Q1 2021 |
 PBLS | $144M | 27.75% | 4.32% | New | Q2 2026 |
 ALMS | $127M | 24.53% | Not reported | Not reported | Q2 2024 |
 ACHV | $38.6M | 7.44% | 5.76% | New | Q2 2026 |
 ALXO | $26.7M | 5.14% | 9.32% | Not reported | Q3 2020 |
 HRMY | $17.2M | 3.31% | 0.81% | -3.5% | Q3 2020 |
 LYEL | $4.74M | 0.91% | 1.44% | Not reported | Q4 2024 |
| Q1 2026 | |||||
| PHVS | $131M | 46.71% | 7.11% | Not reported | Q1 2021 |
| ALMS | $99.8M | 35.56% | Not reported | -2.0% | Q2 2024 |
| ALXO | $25.8M | 9.21% | 9.32% | +32.8% | Q3 2020 |
| HRMY | $13.7M | 4.88% | 0.85% | Not reported | Q3 2020 |
| LYEL | $6.77M | 2.41% | 1.45% | Not reported | Q4 2024 |
 ARTV | $3.42M | 1.22% | 2.15% | -18.1% | Q3 2024 |
| Q4 2025 | |||||
| PHVS | $129M | 59.53% | 7.11% | Not reported | Q1 2021 |
| ALMS | $45.1M | 20.85% | Not reported | Not reported | Q2 2024 |
| HRMY | $18.3M | 8.46% | 0.85% | Not reported | Q3 2020 |
| ALXO | $11M | 5.07% | 17.83% | Not reported | Q3 2020 |
| LYEL | $10.4M | 4.81% | 1.59% | -28.7% | Q4 2024 |
| ARTV | $2.78M | 1.29% | 2.64% | -43.6% | Q3 2024 |
| Q3 2025 | |||||
| PHVS | $116M | 65.62% | 8.53% | +8.2% | Q1 2021 |
| ALMS | $18.4M | 10.45% | Not reported | Not reported | Q2 2024 |
| ALXO | $17.8M | 10.06% | 18.10% | Not reported | Q3 2020 |
| HRMY | $13.5M | 7.64% | 0.85% | Not reported | Q3 2020 |
| LYEL | $7.69M | 4.36% | 2.45% | Not reported | Q4 2024 |
| ARTV | $3.3M | 1.87% | 4.70% | Not reported | Q3 2024 |